Quintrio
Home

PHARMACEUTICAL PREPARATIONS

AYTU BioPharma, Inc. Common Stock

AYTU

Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment. Its product portfolio includes EXXUA, ADHD Portfolio, Pediatric Portfolio, and Other. Majority of revenue comes from ADHD Portfolio. It has presence in United States.

Last trade $2.66
Day change +$0.835 (+45.88%)
Day range $2.53 – $2.67
Volume 4,006,841
Market cap $20M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$19.78M
Price / earnings
—
Price / book
0.56×
Price / sales
0.34×
EV / sales
0.18×
EV / EBITDA
-2.39×

Profitability

Earnings per share
-$1.31
Return on assets
-13.57%
Return on equity
-40.4%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.48×
Current ratio
1.13×
Quick ratio
1×
Cash ratio
0.48×

Cash flow

Price / cash flow
6.03×
Price / free cash flow
6.08×
Free cash flow
$3.25M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AYTU, quarterly periods
Line itemQ4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024Q1 FY2025 Sep 30, 2024
Revenue$16.11M$12.41M$15.17M$13.89M$15.14M$18.45M$16.22M$16.57M
Cost of revenue$5.7M$4.81M$5.54M$4.7M$4.88M$5.65M$5.44M$4.59M
Gross profit$10.41M$7.6M$9.62M$9.19M$10.25M$12.81M$10.79M$11.99M
Selling, general and administrative$10.43M$10.9M$11.07M$10.25M$8.48M$9.3M$9.72M$10.78M
Research and development$0$0$0$0$216K$162K$522K$426K
Total operating expenses$11.19M$11.66M$11.59M$10.69M$17.88M$10.39M$12.48M$12.92M
Operating income-$777K-$4.06M-$1.97M-$1.5M-$7.62M$2.42M-$1.7M-$930K
Interest expense-$383K-$436K-$560K-$516K-$730K-$900K-$1.08M-$994K
Income before taxes-$4K-$5.61M-$10.58M$1.97M-$19.44M$3.82M$382K$1.5M
Income taxes$11K$10K$0$0$437K-$122K-$283K$405K
Net income-$15K-$5.62M-$10.58M$1.97M-$19.82M$3.99M$788K$1.47M
Net income attributable to common shareholders-$15K-$5.62M-$10.58M$1.97M-$19.82M$3.99M$788K$1.47M
EBITDA$344K-$2.94M-$1.09M-$701K$2.1M$3.71M$914K$1.19M
Basic earnings per share$0.00-$0.53-$1.05$0.21-$2.92$0.65$0.13$0.24
Diluted earnings per share$0.00-$0.53-$1.05-$0.08—$0.21-$0.26-$0.15

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue Estimates

Aytu BioPharma reported a quarterly loss of $0.2 per share, missing consensus estimates of $0.1 loss, representing a -100% earnings surprise. The company posted revenues of $14.84 million, slightly beating estimates. With unfavorable estimate revisions, the stock received a Zacks Rank #5 (Strong Sell) rating and has declined 31.5% year-to-date versus the S&P 500's 10.5% gain.

Zacks Investment Research

Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates

Cerenome (CNSY) reported a quarterly loss of $1.14 per share, missing the consensus estimate of $0.98 loss by 16.33%. While revenues of $0.72 million beat estimates by 44.40%, they declined significantly from $1.4 million year-ago. The stock has plummeted 94% since the beginning of 2026 versus the S&P 500's 10.9% gain. Zacks assigned the stock a Hold rating (Rank #3) with mixed estimate revisions ahead.

Zacks Investment Research

Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Misses Revenue Estimates

Zealand Pharma A/S reported a quarterly loss of $0.12 per share, beating consensus estimates of $1.33 loss by 90.98%, but revenues of $0.62 million missed estimates by 97.57%. The stock has declined 48.7% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates

CytomX Therapeutics reported a quarterly loss of $0.09 per share matching consensus estimates, but revenues of $1.69 million missed expectations by 59.68%, down significantly from $5.96 million year-ago. The stock has declined 44.8% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 45% of sectors.

Zacks Investment Research

Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?

Elite Pharmaceuticals (ELTP) and Aytu BioPharma (AYTU) are two pharmaceutical companies with CNS and ADHD market exposure, but with different strategies. ELTP focuses on generic pharmaceuticals with an expanding pipeline and strong financial position, while AYTU emphasizes branded medicines centered on its EXXUA growth catalyst. Despite both trading below sector valuations, ELTP is recommended as the better buy due to its broader commercial base, lower execution risk, and improving operating momentum, while AYTU presents a higher-risk turnaround story dependent on EXXUA's success.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 6, 20231-for-20reverse split
Dec 9, 20201-for-10reverse split
Aug 13, 20181-for-20reverse split
Aug 29, 20171-for-20reverse split
Jul 1, 20161-for-12reverse split